Physician profile
Peter A Castillo
NPI 1164521035
$95,291.19
in general payments reported to CMS, 2019-2025
23 companies · $385 in 2025
The $385 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $2,352 · 2021: $2,213 · 2022: $24K · 2023: $3,339 · 2024: $632 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,098 · Travel and Lodging: $1,675 · Consulting Fee: $455 · Education: $99.99 · Gift: $28.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,097.50 |
| Travel and Lodging | $1,675.15 |
| Consulting Fee | $455.00 |
| Education | $99.99 |
| Gift | $28.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $90,322.57 | 2019-2025 | Advantage System, Upsylon, Solyx Sis System |
| Axonics, INC. | $1,415.25 | 2021-2023 | Axonics |
| Valencia Technologies Corporation | $862.13 | 2022-2025 | Ecoin Device Kit |
| Medtronic, INC. | $455.00 | 2023 | |
| Caldera Medical, INC | $377.46 | 2022-2024 | Desara |
| Astellas Pharma US INC | $362.01 | 2019-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $296.85 | 2019-2022 | |
| Coloplast Corp | $267.83 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $141.20 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $133.86 | 2024-2025 | Gemtesa |
| Abbvie INC. | $119.62 | 2024-2025 | |
| Allergan, INC. | $106.86 | 2019-2022 | |
| Bluewind Medical | $65.47 | 2024-2025 | Revi |
| Galderma Laboratories, L.P. | $61.99 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $61.93 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $44.61 | 2025 | Zepbound, Mounjaro |
| Medline Industries Lp | $44.00 | 2019 | |
| Acella Pharmaceuticals, LLC | $39.61 | 2024-2025 | NP Thyroid 60 |
| Coopersurgical, INC. | $26.07 | 2022 | |
| Amag Pharmaceuticals, INC. | $23.40 | 2019 | |
| Laborie Medical Technologies Corp. | $22.28 | 2025 | |
| Olympus America INC. | $20.88 | 2020 | |
| Merz North America, INC. | $20.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.